Related Experiment Video
Updated: May 22, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Inhibition of PDE-4 and PDE-5 Differentially Modulates Isolated Porcine Urethral Contractility
Eriq Burovski1, Donna Sellers1, Russ Chess-Williams1
1Centre for Urology Research, Faculty of Health Sciences & Medicine, Bond University, 14 University Drive, Robina, Gold Coast, QLD, 4226, Australia.
Phosphodiesterase-4 (PDE-4) inhibitors relax urethral smooth muscle and reduce contractions. PDE-5 inhibitors aid smooth muscle relaxation with nitric oxide, suggesting distinct PDE roles in urethral tissues.
Area of Science:
- Pharmacology
- Urology
- Smooth Muscle Physiology
Background:
- Phosphodiesterase (PDE) enzymes regulate intracellular signaling pathways, including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
- Differential expression and function of PDE isoenzymes in various tissues suggest specific roles in physiological processes.
- Understanding PDE activity in urethral tissues is crucial for elucidating mechanisms of smooth muscle and mucosal layer contractility.
Purpose of the Study:
- To investigate the impact of phosphodiesterase-4 (PDE-4), PDE-5, and PDE-1 inhibitors on porcine urethral smooth muscle and mucosal layer contractility.
- To differentiate the roles of cAMP and nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathways in urethral tissue function.
Main Methods:
- Organ bath experiments were conducted using isolated porcine urethral tissues (mucosa-intact smooth muscle, mucosa-denuded smooth muscle, and mucosal layers).
- The effects of PDE inhibitors rolipram, roflumilast (PDE-4), sildenafil, tadalafil (PDE-5), and vinpocetine (PDE-1) were assessed across a concentration range (0.1 nM to 10 μM).
- Nitric oxide donor sodium nitroprusside was used to evaluate the role of the NO/cGMP pathway in PDE-5 inhibitor efficacy.
Main Results:
- PDE-4 inhibitors (rolipram, roflumilast) significantly relaxed mucosa-intact urethral smooth muscle and decreased spontaneous contraction rates in mucosal strips.
- PDE-5 inhibitors (sildenafil, tadalafil) relaxed mucosa-denuded smooth muscle but required an exogenous nitric oxide source for relaxation of mucosa-intact tissues.
- The PDE-1 inhibitor vinpocetine demonstrated minimal effects on urethral tissue contractility.
Conclusions:
- The cAMP pathway, modulated by PDE-4, appears to influence spontaneous contractions within the urethral mucosa.
- The NO/cGMP pathway, targeted by PDE-5 inhibitors, is critical for regulating tonic contractions in urethral smooth muscle.
- These findings highlight distinct functional roles for different PDE isoenzymes within the complex architecture of urethral tissues.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators

